The Leader trial (the Lung Cancer Mutation Consortium) has developed a collaborative protocol to screen patients suffering from stage IA2-IIIA NSCLC through tissue- or blood-NGS for assessing the incidence of 10 molecular gene drivers, including ALK, in early-stage disease (NCT04712877). The gene discussed is ALK; the disease is lung carcinoma.